You're signed outSign in or to get full access.
Ra Capital Management, L.P.
RA Capital Management, L.P. is a Boston-based investment firm founded in 2001, specializing in public and private investments in the biotechnology and life sciences sectors. The firm is led by Peter Kolchinsky and Rajeev Shah, and manages significant assets with a focus on innovative healthcare companies. It serves institutional investors and invests across venture capital and public equities strategies, with a dedicated team of over 51-200 employees. RA Capital's expertise centers on supporting transformative science and high-impact healthcare solutions.
Investment Strategy
RA Capital Management pursues a fundamentally driven investment strategy by investing in companies developing groundbreaking solutions in biotechnology, pharmaceuticals, and healthcare. The firm invests across both private and public markets, often supporting companies through multiple stages of their development. Its approach includes deep scientific diligence, a focus on transformative therapeutic areas, and long-term partnership with innovative companies aiming to address unmet medical needs.
Latest 13F Filing Activity
Ra Capital Management, L.P. filed their most recent 13F report on Jun 30, 2025 disclosing 61 equity positions with a total 13F market value of $6B. The fund increased holdings in Ascendis Pharma A/s - Adr, Cidara Therapeutics Inc., Sionna Therapeutics Inc. among other positions. Ra Capital Management, L.P. reduced exposure to Vaxcyte Inc., Edgewise Therapeutics Inc., Apogee Therapeutics Inc. among others.
Top Holdings
Equity Positions (61)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
A ASND | ASCENDIS PHARMA A/S - ADR | 29.90% | $1.77B | 10,281,496 | $82.86 | $172.60 | +$172.1M |
P PCVX | VAXCYTE INC | 6.55% | $389.0M | 11,965,991 | $40.28 | $32.51 | -$71.2M |
R RYTM | RHYTHM PHARMACEUTICALS INC | 5.92% | $351.4M | 5,561,359 | $26.73 | $63.19 | +$29.1M |
J JANX | JANUX THERAPEUTICS INC | 4.35% | $258.5M | 11,189,693 | $27.51 | $23.10 | -$43.6M |
R RNA | AVIDITY BIOSCIENCES INC | 3.48% | $206.4M | 7,266,031 | $31.37 | $28.40 | +$20.4M |
Industry Allocation
Investment Team (42)
| Name | Role | Location | |
|---|---|---|---|
 | Associate | Boston, MA , United States | |
A Alexander Becker | Senior Associate | Boston, MA , United States | |
 | Associate | Cambridge, MA , United States | |
 | Associate | Boston, MA , United States | |
 | Principal | New York, NY , United States | |
| Associate | Boston, MA , United States | ||
B Brian L | Analyst | Boston, MA , United States | |
 | Principal | San Francisco, CA , United States | |
D David Migl | Analyst | United States | |
F Fuad Naser | Analyst | Boston, MA , United States |
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more